In this slideshow, we highlight a Brazilian study that examines the effects of biologics on the three most common psoriasis comorbidities: Metabolic syndrome, cardiovascular disease and fatty liver disease.
Psoriasis is associated with an extensive list of comorbidities ranging from erectile dysfunction to bronchial asthma. But there are three that are exponentially more common than others:Â Metabolic syndrome, cardiovascular disease and fatty liver disease. In this slideshow, we highlight a Brazilian study that examines the effects of treatment with infliximab, adalimumab, etanercept and ustekinumab in psoriasis patients with these three comorbidities.Â
Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin. 2015;33:41-55. Voiculescu VM, Lupu M, Papagheorghe L, Giurcaneanu C, Micu E. Psoriasis and Metabolic Syndrome - scientific evidence and therapeutic implications. J Med Life. 2014;7:468-71. Ogdie A, Schwartzman S, Eder L, Maharaj AB, Zisman D, Raychaudhuri SP, et al. Comprehensive treatment of psoriatic arthritis: managing.comorbidities and extraarticular manifestations. J Rheumatol. 2014;41:2315-22.
